Where does Nabriva Therapeutics GMBH rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Nabriva Therapeutics GMBH ranks #32,568 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Nabriva Therapeutics GMBH hold?

Nabriva Therapeutics GMBH holds 8 US utility patents granted between 2015 and 2024, spanning 7 technology areas.

What is Nabriva Therapeutics GMBH's Innovation Score?

Nabriva Therapeutics GMBH has an Innovation Score of 34.5 out of 100 (48th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Nabriva Therapeutics GMBH focus on?

Nabriva Therapeutics GMBH's top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 6 patents, ranking #2,984 of 6,058 assignees active in that subclass. Grants appear in 7 CPC subclasses total.

Is Nabriva Therapeutics GMBH's patent grant rate increasing or decreasing?

Nabriva Therapeutics GMBH's recent grant velocity is -67% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Nabriva Therapeutics GMBH's patents?

Nabriva Therapeutics GMBH's patents average 18.1 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Nabriva Therapeutics GMBH patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Nabriva Therapeutics GMBH

USPTO PatentsView assignee record - 8 granted patents across 7 technology areas, recorded in grant years 2015–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Nabriva ranks #32,568 of 49,997 tracked US assignees by granted-patent volume, with 8 patents across 7 technology areas.

#32,568
of 49,997 US assignees by volume: 48th percentile
by Innovation Score (34.5/100): 18.1
avg claims per patent: -67%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R32568 · Foreign Corporation #32,568 · 8 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-DROP · BOOK-FULL

GRANTS-MICRO 8 grants
MID-PACK #32,568/49,997
PHOTO-FINISH Mynette
CPC-NARROW A61P · 7 areas
INNOV-THIN 34.5/100
CLAIMS-RICH 18.1 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DROP -67% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Mynette Technologies, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Nabriva’s 34.5 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 7.6 pts (22%) Velocity 6.7 pts (19%) Breadth 9.4 pts (27%) Claim depth 10.9 pts (32%)

Qualcomm Incorporated · highest

85
Nabriva Therapeutics · this assignee

34
3D Lighting… · lowest

7

What this shows Nabriva's Innovation Score is 34.5/100 (48th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Nabriva?

Each dot is one of Nabriva’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Nabriva’s own 18.1 claims/patent is ABOVE the 13.9 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Nabriva vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Nabriva's grants concentrate

Nabriva Therapeutics GMBH is a focused PatentsView assignee: 7 CPC subclasses with 75% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2015 (4 grants) versus a trough of 1 in 2016. By volume, Nabriva sits between Mynette Technologies, Inc. and Nanalysis Corp..

Nabriva's three-year grant acceleration

Nabriva Therapeutics GMBH shows 1 grants in 2022–2024 against only 1 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Mynette

8
Mysteryvibe

8
N&W Global Vendin…

8
N99

8
Nabsys 2 0

8
Naieel Technology

8
Najran University

8
Nanalysis

8
Nabriva Therapeut… ◀

8

What this shows Nabriva holds 8 patents at rank #32,555, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Nabriva

By rank, the assignees closest to #32,555 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Nabriva's primary technology class.

Nabriva's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

34 48th percentile higher than 48% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Nabriva Therapeutics GMBH patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	4	50.0%
2016	1	12.5%
2017	1	12.5%
2021	1	12.5%
2024	1	12.5%

Which technologies does Nabriva Therapeutics GMBH patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 6

C07C - Acyclic OR Carbocyclic Compounds 6

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 5

C07D - Heterocyclic Compounds 3

Y02A - Technologies FOR Adaptation TO Climate Change 3

Y02P - Climate Change Mitigation Technologies IN THE Production OR Processing OF Goods 2

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 1

Top 7 of 7 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Nabriva Therapeutics GMBH's patent record in context - here's where to go next.

Nabriva Therapeutics GMBH's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 75% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #32,568 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Nabriva Therapeutics GMBH against Mynette Technologies, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 34.5/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.